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OCT, ERGAlthough visual processing impairments are common in schizophrenia, it is not clear to what extent these orig-
inate in the eye vs. the brain. This review highlights potential contributions, from the retina and other structures
of the eye, to visual processing impairments in schizophrenia and high-risk states. A second goal is to evaluate the
status of retinal abnormalities as biomarkers for schizophrenia. The review was motivated by known retinal
changes in other disorders (e.g., Parkinson’s disease, multiple sclerosis), and their relationships to perceptual
and cognitive impairments, and disease progression therein. The evidence reviewed suggests two major conclu-
sions. One is that there are multiple structural and functional disturbances of the eye in schizophrenia, all of
which could be factors in the visual disturbances of patients. These include retinal venule widening, retinal
nerve ﬁber layer thinning, dopaminergic abnormalities, abnormal ouput of retinal cells as measured by electro-
retinography (ERG), maculopathies and retinopathies, cataracts, poor acuity, and strabismus. Some of these are
likely to be illness-related, whereas othersmay be due tomedication or comorbid conditions. The second conclu-
sion is that certain retinal ﬁndings can serve as biomarkers of neural pathology, and disease progression, in
schizophrenia. The strongest evidence for this to date involves ﬁndings of widened retinal venules, thinning of
the retinal nerve ﬁber layer, and abnormal ERG amplitudes. These data suggest that a greater understanding of
the contribution of retinal and other ocular pathology to the visual and cognitive disturbances of schizophrenia
is warranted, and that retinal changes have untapped clinical utility.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Visual processing impairments are well established in schizophre-
nia, including abnormalities in contrast sensitivity (Kelemen et al.,
2013; Kiss et al., 2010); various excitatory and inhibitory functions
(Kaplan and Lubow, 2011; Keri et al., 2005a; Robol et al., 2013) includ-
ing those involved in masking (Green et al., 2011) and surround sup-
pression (Tibber et al., 2013); and form and motion processing (Chen,
2011; Green et al., 2011; Javitt, 2009; Silverstein and Keane, 2011).
There has been little work on color processing to date (Shuwairi et al.,
2002), but clinical reports indicate frequent descriptions of increased in-
tensity, or alterations in color perception (Chapman, 1966; Vollmer-
Larsen et al., 2007). One study reported a 62% incidence of visual distor-
tions in schizophrenia, with brightness, contrast, and motion increases
being themost commonly reported (Phillipson andHarris, 1985). Visual
distortions also had the highest predictive validity, among all basic
symptoms, for conversion to a psychotic disorder (Klosterkotter et al.,
2001), and visual distortions in help-seeking adolescents are associated
with suicidal ideation, even after controlling for age, gender, depression,
thought disorder, paranoia, and auditory distortions (Grano et al.,
2015). Finally, visual impairments contribute substantially to poorer
real-world functioning in people with schizophrenia (Green et al.,
2012; Rassovsky et al., 2011).al Health Care, Rutgers Biomed-
ay, NJ 08854.
ilverstein).
. This is an open access article underIn spite of this growing body of evidence, an unanswered question is
the extent to which the problems observed in recent laboratory or clini-
cal reports are due to changes in the eye vs. in the brain. It has already
been shown that abnormalities (i.e., hypo- or hyper-activation) exist in
occipital (Butler et al., 2013; Silverstein et al., 2009), temporal
(Silverstein et al., 2010a), parietal (Dima et al., 2009), and prefrontal
(Dima et al., 2009; Silverstein et al., 2009, 2010b) regions during visual
processing tasks in schizophrenia, depending on the nature of the task
requirements. These ﬁndings are thought to reﬂect both inefﬁcient
stimulus-driven (i.e., bottom-up) processing, as well as deﬁcient top-
down guidance or modulation of the feedforward sweep of information
based on prior knowledge, expectations, and task strategies (Dima et al.,
2009, 2010, 2011; Keane et al., 2013; Silverstein and Keane, 2009). How-
ever, degraded input to the visual system could contribute to both
sets of ﬁndings, by adding noise to (or lowering the resolution of)
sensory information, which would disrupt stimulus-driven process-
ing, and by making it less likely that appropriate stimulus templates
ormemory representationswould be activated tomodulate processing. It
is the purpose of this review to: 1) highlight potential mechanisms by
which schizophrenia, or its treatment, can disrupt retinal function and
lead to some of the common laboratory ﬁndings or visual distortions re-
ported by patients; and 2) describe other types of ocular dysfunction
that may contribute to these visual impairments. The extent to which
these retinal and other ocular changes can serve as biomarkers for
schizophrenia or psychosis will also be highlighted.the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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high-risk states
The retina is an active information processor, in which, among other
things, early forms of transformations traditionally thought to occur
only in visual cortex, take place. For example, in response to moving
stimuli, cone photoreceptors produce motion blur, which has been
shown to enhance information about orientation anddirection ofmove-
ment, shape contour orientation and completion, changes in texture be-
tween stimulus regions, spatial frequency, and depth (van Tonder,
2010). Motion blur can also affect perception of complex stimuli such
as facial emotions. Importantly, much input to cone photoreceptors
(the photoreceptor type involved in color vision) is dopaminergic,
and, as reviewed below, retinal dopamine (DA) abnormalities could
contribute to several forms of visual impairments in schizophrenia. An
implication of this is that anything that affects retinal function may re-
sult in intensiﬁed, degraded or noisy input to higher levels of processing
in LGN and visual cortex, depending on the nature of the abnormality.
The retina develops from the same tissue (neuroectoderm) as the
brain, and is the only part of the central nervous system that can be
seen with the naked eye in its natural state in living organisms. Given
that retinal changes may parallel, or mirror the integrity of brain struc-
ture and function (Chu et al., 2012; Kemenyova et al., 2014; Lee et al.,
2013; Tian et al., 2011), it has been suggested that retinal changes can
serve as a marker of progressive brain tissue loss. Given this, the well-
documented structural and functional brain changes in schizophrenia,
and the obvious implications of altered retinal function for changes in
visual processing, what is the evidence for retinal abnormalities
in schizophrenia?
Data from the Dunedin longitudinal study indicated that, at age 38,
individuals with schizophrenia had wider retinal venules than cohort
members who did not have schizophrenia, suggesting a history of
chronic insufﬁcient brain oxygen supply (Meier et al., 2013). This ﬁnd-
ing was not secondary to other health issues. Moreover, wider retinal
venules were associated with extent of psychotic symptoms in adult-
hood, and in childhood. The association between wider retinal venule
width and psychosis (assessed 6 years after the eye exam) was recently
replicated in two Australian twin studies (Meier et al., 2015). Moreover,
retinal venulewidth in unaffected twins of a psychotic siblingwas char-
acterized by values intermediate between controls and psychotic sib-
lings. Arteriole width was unaffected by presence of psychosis in
twins with psychosis or their unaffected siblings. These data suggested
that retinal venule widening may be a proxy marker of familial risk for
psychosis. Other evidence indicates that retinal venule width is signiﬁ-
cantly correlated with childhood IQ and with neuropsychological func-
tioning at midlife, in the general population (Shalev et al., 2013). A
similar recent ﬁnding is that, in the general population, color vision im-
pairments [implying DA dysregulation in cone photoreceptors (see
below)] predict difﬁculties with cognitive control (Colzato et al.,
2014) — a function thought to involve dopaminergic projections to
the prefrontal cortex (van Schouwenburg et al., 2010), and that is char-
acteristically impaired in schizophrenia (Lesh et al., 2011). These data
suggest that basic aspects of retinal structure and function may indicate
increased risk for schizophrenia, and be impaired in the disorder, via
reﬂecting reduced vascular and brain health.
Other evidence for structural retinal changes in schizophrenia comes
from studies of optical coherence tomography (OCT). OCT is a recently
developed, rapid, non-invasive imaging technique that can reveal reti-
nal structure in vivowith axial resolutions of 5microns or less. It has re-
cently proven useful for identifying thinning of certain retinal layers in
several neurological conditions such as multiple sclerosis (MS)
(Khanifar et al., 2010; Martinez-Lapiscina et al., 2014), Parkinson’s dis-
ease (Satue et al., 2013, 2014; Tian et al., 2011), and Alzheimer’s disease
(Moschos et al., 2012), in addition to focal eye diseases (Leung et al.,
2010). Retinal nerve ﬁber layer (RNFL) thinning – reﬂecting loss of gan-
glion cell axons that leave the retina as the optic nerve and synapse ontothe lateral geniculate nucleus – as revealed by OCT, is thought to be a
good model of brain neurodegeneration, since retinal cells are unmy-
elinated, and so any thinning directly reﬂects cell loss (Lee et al.,
2013). Consistent with this, progressive RNFL thinning parallels disease
progression in Parkinson’s disease (Tian et al., 2011), where level of
thinning correlates signiﬁcantly with extent of visual hallucinations
(Lee et al., 2014) and functional disability (Satue et al., 2014). In MS,
RNFL thinning is associated with duration of illness, gray matter loss,
poorer executive functioning, poorer overall cognitive functioning, ill-
ness progression, and relapse (Martinez-Lapiscina et al., 2014;
Ratchford et al., 2013; Saidha et al., 2013; Sedighi et al., 2014; Toledo
et al., 2008). Interestingly, even in healthy subjects, OCT indices corre-
late with intracranial volume (Saidha et al., 2013). OCT studies of
schizophrenia have focused onRNFL thinning and reductions inmacular
volume (MV) (reﬂecting integrity of the fovea and surrounding tissue).
While an initial small study (n=10 patients) reported RNFL thinning
(Ascaso et al., 2010), this was not replicated in a subsequent study
(Chu et al., 2012), although in the latter, reduced MV was related to in-
creased positive symptoms. However, this study used an earlier gener-
ation (time domain) OCT device characterized by an ~10 micron axial
resolution generating 400 scans per second. More recent studies,
using spectral-domain OCT with resolution of ~5 microns and over
25,000 scans per second, have observed both RNFL and MV thinning
(Lee et al., 2013), or RNFL thinning only (Cabezon et al., 2012), in
schizophrenia (see Figs. 1 and 2). As with retinal venule widening, the
functional signiﬁcance of these ﬁndings is not yet clear, although one
study found that RNFL thinning was related to illness chronicity in
schizophrenia (Lee et al., 2013). Studies investigating the relationship
between retinal degeneration and visual processing are just beginning
to be carried out with schizophrenia patients. However, it is thought
that problems in visual processing (including in contrast sensitivity,
color perception, and reading) in Parkinson’s diseasemay be due to ret-
inal cell loss (Djamgoz et al., 1997; Harnois and Di Paolo, 1990; Hutton
and Morris, 2001; Rodnitzky, 1998), and similar problems have been
observed in schizophrenia (Butler et al., 2005; Cadenhead et al., 2013;
Kelemen et al., 2013; Revheim et al., 2006b, 2014) (see below). In addi-
tion, as described in the next section, ganglion cell loss (which may be
the primary cause of RNFL thinning) may be a marker of other cellular
processes that have been linked to speciﬁc visual impairments. An addi-
tional consideration for studies of schizophrenia is that diabetic retinal
changes (maculopathy) detectable by OCT (Sikorski et al., 2013) could
contribute to visual processing disturbances, and so must be ruled out
in both eyes of patients.
2. Dopamine and retinal function
DA is amajor neurotransmitter in the vertebrate retina, and its cellu-
lar localization and functions are similar in organisms as diverse as ﬁsh
and primates (Djamgoz et al., 1997; Masson et al., 1993). In the retina,
DA originates in one class of amacrine cells (ACs) and in interplexiform
cells. It is transmitted via standard synaptic transmission, as well as by
volume transmission, where it can diffuse up to 3 mm through retinal
tissue to potentially inﬂuence every type of retinal neuron, as all have
receptors for DA (Yazulla and Studholme, 1995). One important func-
tion of DA in the retina is to weaken the gap junctions that couple hor-
izontal cells (Piccolino et al., 1984; Teranishi et al., 1983). Because
horizontal cells (HCs) pool the activity of photoreceptor cells across
space, this DA-related uncoupling leads to signiﬁcant reduction of the
normally large HC receptive ﬁelds (Xin and Bloomﬁeld, 2000), and to
increased sensitivity to local (relative to contextual) stimulation
(Brandies and Yehuda, 2008). A second effect of the uncoupling of HCs
is reduced interaction between neurons signaling light and dark por-
tions of space, leading to enhanced center responses (and reduced ef-
fects of surround responses) (Hedden and Dowling, 1978).
The DA receptor types found in the retina are the same as those
found in the brain (e.g., D1–D5), and can be roughly divided into D1
Fig. 1.Macular thinning, as shown in a representative patient with schizophrenia in an ongoing study of the authors. Left panel: gray-scale image of the macula from right eye of patient.
Central colorized panel is a topographic map overlay (50% transparency) showing thickness (in μm) from the inner limiting membrane (ILM, which covers the retinal nerve ﬁber layer;
see Fig. 2) to the retinal pigment epithelium (RPE, which is beneath the photoreceptor layer). Thickness scale is depicted by the legend on right side of ﬁgure. Right panel: average thickness
values of the segments are colorized relative to age-matched control subjects. Regions in yellow denote values observed in less than 5% of age-matched subjects; regions in pink–red denote
values observed in less than 1% of age-matched subjects. This patient demonstrates borderline signiﬁcant or signiﬁcant thinning in more than half of the macular subregions in this eye.
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suprathreshold rod-mediated ON and OFF responses. However, with
cones, DA increases excitation for ON responses, and increases inhibi-
tion for OFF responses in most cases (Popova and Kupenova, 2013). It
is thought that D2 receptors are primarily involved in generating ON re-
sponses,whereas D1 receptors aremainly responsible for OFF responses
(Popova and Kupenova, 2013). As a result of these asymmetries, excess
DA at D2 receptors can lead to hyper-intense color perception (as seen,
for example, in early schizophrenia, see below), whereas reduced DA
can lead to reductions in color perception (as seen, for example, in
Parkinson’s disease, see below).
Taken together, these data suggest that the excesses and reductions
in DA activity repeatedly demonstrated in the brain in schizophrenia are
likely to also occur in the retina, where they may play a signiﬁcant role
in visual processing disturbances. In the following two subsections, each
of these scenarios, and their implications for understanding results of vi-
sual experiments in schizophrenia, is discussed.
2.1. Effects of reduced retinal DA on vision
Through studies of Parkinson’s disease patients (including post-
mortem studies), along with animal and human studies of drug-
induced Parkinsonian symptoms (Bodis-Wollner and Tagliati, 1993;
Bulens et al., 1989), it is known that retinal DA is reduced in this condi-
tion (Tian et al., 2011). Reduced retinal DA leads to excessively strong
coupling of HCs and ACs, leading to increased inhibition, and subse-
quently to reduced contrast sensitivity and poorer color vision andFig. 2. Retinal nerve ﬁber layer (RNFL) thickness map represents the thickness of the layer of ga
from a representative patient with schizophrenia in an ongoing study of the authors. Left and
corrected thickness values observed in less than 5% of the general population. Areas in pink–red
actual thickness values in temporal (TEMP), superior (SUP), nasal (NAS), and inferior (INF) reti
red shaded areas represent the same age-normed values as in the left and right panels. This patie
RNFL quadrants, and borderline signiﬁcant (b5% of the population) thinning in the left nasal qvisual acuity (Djamgoz et al., 1997). Monkeys administrated MPTP or
intraocular 6-OHDA (both of which destroy retinal DA neurons and re-
duce levels of retinal DA) show reduced processing of mid-range spatial
frequencies (e.g., 2.5–3.5 cycles/degree) (Bodis-Wollner and Tagliati,
1993), and these changeswere temporarily reversed by L-DOPA admin-
istration (Bodis-Wollner, 1990). Humanswith drug-induced Parkinson-
ism have demonstrated a general reduction in contrast sensitivity
across all spatial frequencies (Bulens et al., 1989), and the contrast sen-
sitivity impairments in patients with Parkinson’s Disease can be re-
versed (with less strong effects at high spatial frequencies) after L-
DOPA administration (Bulens et al., 1987). In addition, elderly subjects
from the general population, who typically show poor low spatial fre-
quency (LSF) processing, demonstrated improved processing across
the full range of spatial frequencies after 3 months of treatment with
the D2 agonist piribedil (Corbe et al., 1992). Moreover, in children
and/or adultswith amblyopia, a single dose of L-DOPA (but not placebo)
signiﬁcantly increased contrast sensitivity (Gottlob and Stangler-
Zuschrott, 1990) and visual acuity (Leguire et al., 1992), and effects on
acuity were 3 times stronger after a week of L-DOPA (Gottlob et al.,
1992). Of note, these effects were obtained regardless of whether con-
trast was measured at, or above, detection threshold (Brandies and
Yehuda, 2008). Finally, in healthy rats and humans, haloperidol
(Haldol), including a single dose, delayed visual evoked potentials
(VEPs) (reviewed in (Brandies and Yehuda, 2008)). These data are rele-
vant to schizophrenia, because people with this condition typically take
DA receptor antagonists, and have also demonstrated longer latency
VEPs (Malyszczak et al., 2003), and problems in visual acuity (Viertionglion cell axons that leave the retina as the optic nerve. There is thinning of focal sectors
right panels depict right and left eyes, respectively. Areas shaded yellow represent age-
represent values observed in less than 1% of the general population. Center panel depicts
nal quadrants, for the left (dashed line) and right (continuous line) eyes. Yellow and pink–
nt demonstrates signiﬁcant (b1% of the population) thinning in both left and right inferior
uadrant.
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Slaghuis, 1998), and LSF processing (Martinez et al., 2008, 2012), al-
though the latter impairment is not always found (Keane et al., 2014a;
Laprevote et al., 2010, 2013), and it may not be speciﬁc to low spatial
frequencies (Skottun and Skoyles, 2007).
The similarities between schizophrenia and Parkinson’s disease
discussed above raise the question: are the ﬁndings in schizophrenia
due to disease-related retinal DA reductions, or to receptor blockade
secondary to antipsychotic medication? Data on this issue suggest that
antipsychotic medication can have negative effects on visual function.
For example, while antipsychotic medication in general did not impair
visual acuity (which was reduced in subjects with schizophrenia), phe-
nothiazines in particular were shown to impair near (but not far) acuity
through their effect on ciliary muscle accommodation responses
(Viertio et al., 2007), which is most relevant to reading and performing
laboratory visual processing tasks. A recent study found impaired con-
trast sensitivity for both chromatic and achromatic stimuli in schizo-
phrenia, with some evidence for more normal chromatic contrast
sensitivity in unmedicated patients (Cadenhead et al., 2013). Similarly,
in an earlier study, in amixed group of psychiatric patients that included
many with schizophrenia, administration of antipsychotic mediation
led to a global decrease in contrast sensitivity compared to controls
(Bulens et al., 1987). This was later replicated in a study demonstrating
that schizophrenia patients on typical antipsychotic medications dem-
onstrated poorer contrast sensitivity compared to both healthy controls
and patients on atypical medications (Chen et al., 2003). In some cases,
these decreases in contrast sensitivity are dose-dependent (Keri et al.,
2002). Some studies of schizophrenia patients, however, have found
that administration of antipsychotic medications decreases contrast
sensitivity for medium and high spatial frequencies (Harris et al.,
1990; Keri et al., 2002), and increases it at low spatial frequencies
(Harris et al., 1990). Further evidence suggests that the combination of
antipsychotic and antidepressantmedication [a combination frequently
prescribed due to high rates of depression in schizophrenia (Siris,
2000)] is especially detrimental to contrast sensitivity (Sheremata and
Chen, 2004). It should be noted here that antipsychotic medications
can interfere with vision in ways other than by reducing retinal DA, as
instances of toxic maculopathy (Lee and Fern, 2004) and increased
risk for cataract (McCarty et al., 1999) have been reported. However,
these are far less likely to occur than the DA-depleting effects. Finally,
in over half of a group of previously untreated schizophrenia patients,
VEP latency increased after initiation of antipsychotic medication
(Bodis-Wollner et al., 1982).
One consequence of retinal DA receptor blockade is less input to ret-
inal ganglion cells, which has been proposed as a mechanism of gangli-
on cell atrophy in Parkinson’s Disease (Tian et al., 2011). This raises the
intriguing possibility that the RNFL abnormalities reviewed in the sec-
tion above may be secondary to antipsychotic (and perhaps other)
medication use.
2.2. Effects of excess retinal dopamine on vision
Evidence from single-photon emission computed tomography
(SPECT) and positron emission tomography (PET) studies supports
the traditionally held view that the acute psychotic phase of schizophre-
nia is characterized by hyperdopaminergia (e.g., an exaggerated re-
sponse of DA neurons), whereas functioning of the DA system
approaches normal levels in periods of symptom remission (Kegeles
et al., 2010; Laruelle et al., 1999). Therefore, changes in vision during
acute psychotic episodes should be expected to be the opposite of
those found with antipsychotic medication administration. Some evi-
dence suggests that this is so. For example, in studies with healthy
adult volunteers, L-DOPA administration improved contrast sensitivity
at medium to high spatial frequencies, and decreased it at lower fre-
quencies (Domenici et al., 1985), and apomorphine also reduced con-
trast sensitivity at low frequencies in a dose-dependent fashion (Blinet al., 1991). These effects were shown not to be a function of attention
span or pupil diameter, suggesting a dopaminergic effect (Blin et al.,
1991). Similar ﬁndingswere demonstrated in unmedicated schizophre-
nia patients, who demonstrated higher contrast sensitivity compared to
healthy controls (Chen et al., 2003). A more complex pattern of results
was reported in a recent study of previously untreated ﬁrst episode
schizophrenia patients (Kelemen et al., 2013). This group demonstrated
greater sensitivity than controls to low, but not medium, spatial fre-
quencies, prior to antipsychotic treatment. After initiation of treatment,
this superiority disappeared, due to a reduction in sensitivity to low spa-
tial frequencies in the schizophrenia group (i.e., not due to changes in
the control group) during the treatment period. Moreover, the normal-
ization (reduction) in LSF processing after treatment occurred in
conjunction with a reduction in self-reported anomalous visual experi-
ences. Importantly, these visual effects were independent of GABA
levels in the visual cortex, which affect visual processing (Rokem et al.,
2011; Yoon et al., 2010) but were unaffected by this treatment, suggest-
ing their possible retinal origin.
Can the ﬁndings of increased LSF processing in untreated ﬁrst epi-
sode patients, with a decrease after treatment (Kelemen et al., 2013),
be reconciledwith the ﬁndings of an increase in LSF processing (and de-
creases in medium and high spatial frequency processing) after treat-
ment in chronic schizophrenia patients (Harris et al., 1990)? This
apparent paradox may reﬂect important differences between the
groups: while the ﬁrst episode patients were characterized by a
hyperdopaminergic state prior to treatment, the chronic patients had
manyyears of treatment,were clinically stable and living in the commu-
nity, and were therefore presumably not in a hyperdopaminergic state
when they were switched to an injectable medication (after which,
the second testingwas done at the pointwhere blood levels of themed-
ication peaked). It is therefore possible that the resultswithﬁrst episode
cases reﬂect movement from hyperdopaminergic to normal levels,
whereas the results with chronic cases reﬂect movement from normal
levels towards hypodopaminergia, similar towhat is observed in studies
of Parkinson’s Disease (Bodis-Wollner and Tagliati, 1993). Even so, the
increase in LSF processing after injectable medication in chronic pa-
tients is curious, and may be a spurious result, given the small sample
size (n= 8), the unclear diagnostic criteria used, and the fact that an in-
crease in LSF processing after treatment was not reported in other stud-
ies. Still, the decrease in medium–high spatial frequency processing
after treatment in these patients is consistent with effects observed in
Parkinson’s disease.
As noted above, excessive retinal DA can be expected to cause effects
such as increased brightness and heightened intensity of color. Each of
these has been reported (in clinical reports) in ﬁrst episode schizophre-
nia (Chapman, 1966), along with a high level of visual distortions
(Bunney et al., 1999; Klosterkotter et al., 2001), and, as predicted, all
of these phenomena decrease after initiation of antipsychotic medica-
tions (Kelemen et al., 2013). In short, available, albeit limited, evidence
suggests that hyperdopaminergia as found in schizophrenia is associat-
ed with excessive LSF processing, and this is consistent with other evi-
dence of exaggerated magnocellular responsivity, and subjective
changes in vision early in the illness (Keri and Benedek, 2007) and
prior to long-term antipsychotic treatment.
3. Other neurotransmitters and retinal function
Glutamate is the major neurotransmitter in the vertebrate retina
(de Souza et al., 2012), is the only output neurotransmitter of the
photoreceptors (Copenhagen and Jahr, 1989), and is also released
by bipolar and ganglion cells (Massey and Miller, 1990) (i.e., cells
providing the feedforward sweep of information within and out of
the retina). Moreover, glutamate output from photoreceptors is
gated by the NMDA-type of glutamate receptor (Copenhagen and
Jahr, 1989). This is potentially relevant to vision in schizophrenia
since: 1) various lines of evidence converge in indicating that
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receptor hypoactivity, leading to increased glutamate release, and
this evidence forms the basis of a leading theory of the etiology of
the condition (Kantrowitz and Javitt, 2010a, b; Moghaddam and
Javitt, 2012; Olney and Farber, 1995); 2) NMDA dysregulation is
known to cause increased DA release (Javitt, 2007), and to produce
visual distortions, hallucinations, and performance on psychophysi-
cal tests of vision that resemble those found in schizophrenia
(Phillips and Silverstein, 2003; Uhlhaas et al., 2007); 3) NMDA an-
tagonists such as ketamine can cause pathological changes in the ret-
ina, including retinal hypoxia and cell death (Antal, 1979), and can
cause reductions in the early (sensory) visual P1 evoked potential
(Lalonde et al., 2006), which is also found in schizophrenia where
it is related to level of positive symptoms (Gonzalez-Hernandez
et al., 2014); and 4) many schizophrenia patients have diabetes, in
many cases due to antipsychotic medication-related metabolic syn-
drome and weight gain, and diabetes is associated with increased
retinal glutamate and retinopathy (Kowluru et al., 2001). To date,
it has not been established that changes in glutamate function exist
in the retina of people with schizophrenia (and therefore that any
such changes contribute to visual functioning in people with schizo-
phrenia). However, given the evidence noted here, we believe this is
as fruitful an area to explore as that of retinal DA changes and vision
in schizophrenia. One question that is particularly relevant is wheth-
er the glutamatergic input to, or from, two types of retinal cells in
particular, midget and parasol cells, is altered. While the functional
properties of these cell types continue to be topics of study, it is gen-
erally agreed that midget bipolar and ganglion cells have small re-
ceptive ﬁelds, are involved in color processing, and project into the
LGN parvocellular pathway (Kolb, 1995; Kolb and Marshak, 2003).
In contrast, parasol ganglion cells, which receive input from DB2
and DB3 type bipolar cells (Jacoby et al., 2000), have large receptive
ﬁelds, project to the LGN magnocellular pathway, and play a role in
contrast sensitivity (Crook et al., 2014). The latter has been found
to be variously underactive or overactive in schizophrenia, depend-
ing on the task, and phase of illness (Butler et al., 2001; Javitt,
2009; Kelemen et al., 2013; McClure, 2001; Schechter et al., 2003),
but retinal contributions to these effects have yet to be described.
Two other prevalent neurotransmitters in themammalian retina are
glycine and GABA (Brandstatter et al., 1998). These neurotransmitters
are involved in the inhibitory connections at horizontal and amacrine
cells, which modulate the output of photoreceptor and bipolar cells.
Studies of retinal connectomics have revealed multiple modes of inhib-
itory input for both GABA and glycine (Robert et al., 2014). Studies of
schizophrenia have also noted abnormalities in these neurotransmitter
systems (Ohnuma et al., 2008; Stan and Lewis, 2012; Yamamori et al.,
2014). To date, however, the issue of contributions of retinal levels of
these neurotransmitters to visual processing disturbances in schizo-
phrenia has not been explored.
4. Electroretinographic changes in schizophrenia
Several studies indicate abnormal a- or b-wave activity in the ERG in
schizophrenia (Lavoie et al., 2014b). The a-wave (late receptor poten-
tial) reﬂects activity in the photoreceptors, whereas the b-wave primar-
ily reﬂects activity in bipolar andMüller cells (other waveforms exist as
well, but, with one exception, see below, these have not been studied in
schizophrenia). Depending on the type of stimulation and background
illumination used, these waveforms can reﬂect varying degrees of rod
vs. cone function. All published studies to date have used the ﬂash
ERG method (pattern ERG and multifocal ERG are also commonly
used in ophthalmology). The initial study of this issue (Marmor et al.,
1988) focused on oscillatory potentials (ﬂuctuations in the rise of the
b-wave) which are thought to reﬂect output of DA-containing amacrine
cells. This study found normal waveforms, but it may have been under-
powered (only 12 patients and 9 controls were studied), no statisticaltests were reported, and all patients were medication withdrawn, sug-
gesting a possible self-section bias towards less severely ill patients. A
later, also small, study of schizophrenia patientswith healthy eyes dem-
onstrated cone a-wave and rod a- and b-wave amplitude reductions,
with these ﬁndings being unrelated to medication dose (Warner et al.,
1999). Reduced a-wave amplitude was conﬁrmed in a later study, but
the effectwas only found after hospitalization for an acute psychotic ep-
isode; after 8 weeks of treatment, ERG indices were normal, suggesting
a state effect. ERG data were normal at both time points in a group of bi-
polar disorder patients (Balogh et al., 2008). In the largest study to date,
comparing 105 schizophrenia patients to 150 controls, patients differed
signiﬁcantly from controls on cone a-wave amplitude, mixed rod-cone
b-wave amplitude and pure rod b-wave amplitude, with trends noted
for other amplitude and latency variables (Hebert et al., 2015). As
with earlier studies, the ﬁndingswere not related to level ofmedication,
or tobacco, use. Finally, reduced rod b-wave amplitude and longer laten-
cies were found in a group of unaffected offspring of parents with
schizophrenia or bipolar disorder (there was no effect of parental diag-
nosis; Hébert et al., 2010). Cone activity was normal, as was rod a-wave
activity in this sample. Althoughmuchmore data are need on this issue,
existing data suggest abnormal retinal function at the level of photore-
ceptors during acute psychosis, and at the level of the bipolar-Müller
cells in patients and high-risk subjects regardless of clinical state. As
with OCT data, it is not clear whether these ﬁndings are causes of later
visual processing impairments, or whether they reﬂect parallel distur-
bances in brain function, or both. One proposed mechanism of ERG ab-
normalities in schizophrenia is reduced omega-3 fatty acid
concentration in retinal tissue, where it is normally very dense. This hy-
pothesis is consistent with data on reduced omega-3 fatty acid levels in
the brain in schizophrenia (Ohara, 2007), with the therapeutic effects of
omega-3 supplementation in schizophrenia (McNamara and Strawn,
2013), andwith known effects of fatty acid depletion on retinal function
and ERG indices (Neuringer et al., 1986). However, it is also hypothe-
sized that ERG abnormalities reﬂect DA and serotonin changes,
paralleling similar changes in the brain (Lavoie et al., 2014a).
5. Visual acuity changes and their implications in schizophrenia
Poor performance on tests of visual perception (and other cognitive
tasks involving visual stimuli) is assumed to reﬂect the process under
investigation, and little attention has been paid to the possibility that re-
duced visual acuity could play a role. We believe this needs to change,
given past ﬁndings of poorer visual acuity in schizophrenia, but not
other psychotic disorder, patients (including that caused by medica-
tion) (Viertio et al., 2007), with one study reporting that close to 70%
of a schizophrenia patient sample had untreated visual acuity problems
(Smith et al., 1997) [although some studies reported lower rates
[e.g., 26% (Souza et al., 2008)] this is still excessive]. While the role of
acuity changes in performance on perceptual (and other) tasks in driv-
ing between group differences in studies of schizophrenia is generally
not known, recent evidence suggests a role. For example, in a study
that matched patients and controls on visual acuity, no differences
were found in low and high spatial frequency processing conditions
(in contrast to many past studies), and, in the sample as a whole, re-
duced high spatial frequency processing was related to lower acuity
(Silverstein et al., 2014). This suggests that at least some prior ﬁndings
of group differences in spatial frequency processing, or where detail
processing is critical to task performance, orwhere visual stimuli are de-
graded (Knott et al., 1999; Nuechterlein et al., 1986), or even in reading
(Revheim et al., 2006a, 2014), could be due, at least in part, to between-
group acuity differences (evenwhen these arewithin the normal range,
see below). It also raises the possibility that the observed bias towards
LSF processing in some studies (Laprevote et al., 2010, 2013) may be
due to an illness-related bias that has developed to preferentially pro-
cess LSFs, even when HSF processing is adequate for the task. But,
even within the range of normal vision (i.e., 20/32 or better), acuity
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healthy controls, people with 20/16 vision performed signiﬁcantly bet-
ter than subjects with 20/20 vision on tests of contour integration and
collinear facilitation (Keane et al., 2014b), two measures on which
schizophrenia patients have performed abnormally in multiple studies
(Keri et al., 2005a, 2005b, 2009; Silverstein et al., 2000, 2009, 2012a).
This was recently replicated in a separate sample of schizophrenia pa-
tients and controls (Keane et al., 2014c). The implication of this is that
demonstrating that all subjects (patients and controls) have “normal
or corrected to normal vision” is not enough, especially since schizo-
phrenia patients, with their poorer health care (Marder et al., 2004) in-
cluding less frequent eye examinations (Viertio et al., 2007)
[including in patients with diabetes (De Hert et al., 2011)], can be
assumed to have poorer acuity than controls even when it is
roughly within the normal range.
Importantly, acuity differences may precede diagnosis. For example,
poorer visual acuity, but not other sensory impairments, at 4 years old
predicted a diagnosis of schizophrenia, but not other psychiatric diagno-
ses, in adulthood (Schubert et al., 2005).
Finally, since many antipsychotic medications have anticholinergic
effects, and these are known to include dilated pupils and blurred vision
(Lieberman, 2004), and similar effects are caused by medications used
to treat movement side effects in schizophrenia (e.g., benztropine),
medication use may compound visual acuity impairments in people
with schizophrenia.
In short, future studies of perceptual impairment in schizophrenia,
or of other functions that involve processing visual stimuli should de-
scribe the extent to which reduced visual acuity contributes to abnor-
mal performance.
6. Ocular abnormalities and their implications for schizophrenia
In addition to acuity differences, other ocular changes related to
schizophrenia, lack of good health care in people with this condition,
and/or to its treatment can affect performance on visual processing
tasks. For example, Smith et al. (1997) reported that 82.6% of a sample
of schizophrenia patients had lens opacities, cataracts, or corneal pig-
mentation. This study also found that cataracts were more common in
patients on ﬁrst-generation (40%), compared to second-generation an-
tipsychotic medications (18%).
Another condition more common in schizophrenia than the general
population is strabismus (Yoshitsugu et al., 2006), or differential align-
ment of the eyes. Elevated rates of strabismus have also been found in
children who later develop schizophrenia (Schiffman et al., 2006). This
can result in amblyopia, and depth perception difﬁculties, and people
with schizophrenia have shown poor performance on visual tasks
such as contour integration that resembles that of people with ambly-
opia (Hess et al., 1997; Kiorpes, 2006; Kovács et al., 2000; Silverstein
et al., 2000, 2009, 2012a), as well as problems with depth perception
(Schechter et al., 2006).
Whether resulting from illness-related processes, general neurolog-
ical vulnerabilities, antipsychotic medication, or a lack of adequate
health care, these conditions can affect visual processing. However, at
least some of these problems are likely to be primary, because children
who later developed schizophrenia in adulthood have been shown to
have poorer ocular alignment (i.e., higher strabismus scale scores)
than children who did not develop schizophrenia (Schiffman et al.,
2006). Whether primary or secondary, however, studies of perception
in schizophrenia typically do not screen for ocular problems, and thus
their contribution to past ﬁndings is not known.
7. Does congenital blindness exert a protective effect against
schizophrenia?
Since 1950 (Chevigny and Braverman, 1950), it has been proposed
multiple times that, since there have been no reports of people withschizophrenia who were born blind, congenital blindness may confer
a complete or partially protective effect against schizophrenia. Two re-
cent reviews have summarized this literature, and explored mecha-
nisms whereby this effect may operate (Landgraf and Osterheider,
2013; Silverstein et al., 2012b). These include: 1) abnormal visual
input that precedes, and characterizes, schizophrenia is eliminated;
2) many of the cognitive functions that are impaired in schizophrenia
are enhanced among the congenitally blind (see Table 1), suggesting
that the cortical reorganization following birth results in a brain that is
essentially protected against the development of this condition; and
3) congenital blindness involves reduced ﬂexibility in language and in
dynamic representation of the body, and these reductions may protect
against thought disorder and alterations in experience of the self, two
additional aspects of schizophrenia. Importantly: 1) these effects are
much reduced if onset of blindness is after the ﬁrst few months of life;
2) other forms of congenital sensory loss do not protect against schizo-
phrenia (and some are associated with increased risk); 3) congenital
blindness does not protect against other psychiatric disorders suggest-
ing that there is a special link between schizophrenia and visual pro-
cessing; and 4) past ﬁndings of an inverse relationship between the
conditions are not due to their relatively low base rates (Silverstein
et al., 2013). However,much remains to be learned about this inverse re-
lationship, which parallels, but appears to be stronger than, the one be-
tween schizophrenia and rheumatoid arthritis (Gorwood et al., 2004;
Mors et al., 1999). For example, there are multiple ways that blindness
can occur, with varying contributions of the eyes, subcortical structures
(e.g., LGN), and visual cortex, and the extent to which these contribu-
tions may vary in their association with schizophrenia is unclear.
8. Conclusions
The evidence reviewed above suggests two major conclusions. One
is that there are multiple structural and physiological disturbances of
the eye associated with schizophrenia, all of which could contribute to
the visual processing impairments, and altered visual experiences
found in the disorder. These include retinal venule widening (possibly
secondary to tissue loss), ganglion cell axon (and possibly cell body)
loss, dopaminergic abnormalities in photoreceptors, reduced GABA-
and glycine-related lateral inhibition, various maculopathies and
retinopathies, cataracts, poor visual acuity, and strabismus. Some of
these are likely to be related to the illness itself, whereas others may
be due to medication use or comorbid conditions such as diabetes
(i.e., diabetic retinopathy). In some cases, it has already been shown
that variability in these phenomena (e.g., visual acuity) affects perfor-
mance on visual processing tasks on which schizophrenia patients
have demonstrated impairment. A second conclusion suggested by the
evidence is that aspects of retinal structure and function can serve as
biomarkers of brain pathology, and disease progression, in schizophre-
nia. The strongest evidence for this to date involves themarkers of wid-
ened retinal venules, thinning of the RNFL, and abnormal ERG (a and
b) waveforms. This and other evidence suggests that the fast and accu-
rate indices provided by ERG, digital retinal imaging, OCT, and even
color vision assessmentmay be useful surrogatemeasures of global cog-
nitive functioning and speciﬁc cognitive impairments (e.g., cognitive
control), as well as of disease progression over time, as is the case in
other CNS disorders such as Parkinson’s disease and MS. Regarding
color perception in particular, more deﬁnitive studies in medicated pa-
tients are needed, as are studies investigating the possibility of height-
ened color sensitivity in unmedicated ﬁrst-episode patients (especially
in those reporting color hue and intensity distortions), to determine
whether there is excessive activity at cone D2 receptors. To our knowl-
edge, such studies have not yet been conducted.
The goal of this reviewwas to highlight potential contributors to the
visual processing abnormalities of schizophrenia and high-risk states
that are local to the retina or other structures of the eye. Themainweak-
ness of the argument is the relatively small amount of direct evidence of
Table 1
Summary of cognitive and brain function enhancements (+) and impairments (−), com-
pared to healthy sighted individuals, in congenital blindness and schizophrenia. Data
reviewed in Silverstein et al. (2012b).
Function Congenital Blindness Schizophrenia
Auditory Perception
▪ Localization + −
▪ Acuity + −
▪ Discrimination + −
▪ Comprehension + −
▪ Categorization + −
▪ Temporal resolution + −
▪ Latency of auditory ERPs +a −b
Auditory Attention
▪ Preattentive processing (e.g., MMN) + −
▪ Selective attention + −
▪ Divided attention + −
Memory
▪ Working memory + −
▪ Short-term memory + −
▪ Long-term memory + −
Language
▪ Lexical decision making +a −b
▪ Abstraction − +
▪ Conceptual inclusiveness − +
▪ Word inventions − +
Construction of subjective experience
▪ Integration via serial processing + −
▪ Holistic processing + −
Olfaction + −
Motor control + −
Body perception + −
Plasticity + −
a Faster than normal.
b Slower than normal.
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orders such as Parkinson’s disease andMS, alongwith the known prob-
lems in acuity and eye disease in schizophrenia, and the relative
consistency in the albeit small number of OCT and ERG studies of schizo-
phrenia, provide sufﬁciently compelling evidence to suggest the need
for further investigation.
Finally, because post-ocular structures, such as the LGN and visual
cortex, also rely on DA, glutamate, GABA and other neurotransmitters,
it will be a challenge to distinguish which effects are local to the retina,
as opposed to subcortical or cortical. Some aspects of visual impairment
in schizophrenia (e.g., involving orientation discrimination) clearly in-
volve cortical contributions due to known properties of visual cortex
(e.g., orientation speciﬁc columns). Others, such as reduced susceptibility
to certain visual illusions, appear to involve reduced inﬂuences of stored
knowledge on perception, reﬂecting altered connectivity between fron-
tal and parietal regions and higher level visual regions (Dima et al.,
2009; Keane et al., 2013). In addition, since, for example, there are ~20
types of retinal ganglion cells, which cover the retina in a mosaic-type
pattern, andwhose output is integrated in the LGN, with each contribut-
ing a different aspect of information about the visual stimulus (Roska and
Meister, 2014), some visual processing impairments may reﬂect abnor-
mal coordination of ganglion cell outputs in the LGN. This is particularly
relevant given that there are abnormalities in coordinating neural activ-
ity that are found throughout the cortex, and that characterize interme-
diate and higher-level visual processing and cognitive impairments
(Phillips and Silverstein, 2003). However, even with functions such as
coordination of ganglion cell output, orientation discrimination, and per-
ceptual organization, as well as higher-level processes such as illusion
perception, visual memory, and visual learning, degraded retinal input
could serve as a rate-limiting factor. In contrast, with lower level visual
processes such as brightness and motion representation, contrast sensi-
tivity, spatial frequency processing, and color processing, retinal contri-
butions have long been acknowledged. Therefore, we believe that a
more comprehensive understanding of the nature of the full range ofvisual processing and visual cognition impairments in schizophrenia re-
quires that retinal contributions be more precisely determined.
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